Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (25800)	9/27/1998 7:15:00 PM
From: Skeeter Bug	Respond to of 32384

cheryl, nice observation regarding editorial slant. uh, what about paying the debt off? ;-)

To: Cheryl Galt who wrote (25800)	9/28/1998 4:05:00 AM
From: Hippieslayer	Respond to of 32384

Hey Cheryl, First, isn't most of the surplus-if it ever materializes-directly from the SS surplus? Besides, doesn't Clinton owe us a tax break like he promised back in 92? Second and most important— a little birdy told me yesterday after coming back from a derm meeting in SF, that Lgnd's drug for KS (panretin) has a very good chance of being DOA (Dead on approval). Like I have posted many moons ago, there was discussion that today's protein inhib cocktails have virtually elimanted KS. The cases are so few and far between that Ligand better hope that Pan. gets other off label uses. Otherwise, the drug will just collect dust on the pharma shelves. Though lgnd's drug was very quickly mentioned via slide presentation-as I was told- it was at least mentioned. What happened to U of W this weekend? Bye for now...